【作者】 张敏道；

【导师】 安立文；

【作者基本信息】 黑龙江中医药大学 ， 中西医结合临床， 2009， 硕士

【摘要】 目的:探讨癃畅颗粒治疗前列腺增生症的临床疗效及对bcl-2基因表达的影响,从而进一步探讨癃畅颗粒治疗前列腺增生的作用机制。方法:选择80例前列腺增生症患者随机分为两组,治疗组40例,口服癃畅颗粒:对照组40例,口服癃闭舒,1个月为1个疗程,两组均治疗3个疗程。对治疗前后临床症状、IPSS、最大尿流率、残余尿量、前列腺体积等指标进行对照分析。实验部分采用大鼠去势后注射丙酸睾酮致前列腺增生法造模,灌胃给药后30d处死。摘取前列腺组织并测量湿重,采用PV两步法对癃畅颗粒和癃闭舒干预的大鼠前列腺增生组织进行bcl-2基因检测及组织病理学观察。结果:临床观察:治疗组总有效率为78.4%,对照组总有效率为64.7%经x~2检验分析,(P＜0.05),两组疗效比较有显著性差异。治疗组疗后临床症状、IPSS、QOL、最大尿流率、残余尿量、前列腺体积均有明显改善,经t检验分析(P＜0.05),治疗后两组疗效比较有显著性差异。实验研究表明:前列腺湿重:空白组0.61±0.03;模型组0.95±0.04;癃闭舒组0.73±0.02;癃畅颗粒低剂量组0.80±0.05;癃畅颗粒中剂量组0.78±0.07;癃畅颗粒高剂量组0.68±0.03;与模型组比较P＜0.05。前列腺指数,各组分别为:0.143±0.006;0.226±0.008;0.172±0.004;0.199±0.012;0.181±0.010;0.168±0.003;与模型组比较P＜0.05。癃畅颗粒对BPH大鼠前列腺上皮细胞bcl-2基因表达影响(平均光密度),各组分别为:0.089±0.010;0.131±0.005;0.093±0.015;0.109±0.001;0.097±0.003;0.091±0.003;与模型组比较P＜0.05。结论:1.癃畅颗粒治疗前列腺增生症疗效显著,且疗效优于癃闭舒。2.癃畅颗粒能够有效缩小模型大鼠前列腺湿重,减轻病理变化。其作用机制可能为下调大鼠前列腺bcl-2基因表达促进前列腺细胞凋亡。更多还原

【Abstract】 Objective:To investigate the Longchangkeli treatment of benign prostatic hyperplasia and the clinical efficacy of bcl-2 gene expression to explore the impact of particles on the treatment of retention of urine Chang mechanism of benign prostatic hyperplasia.Methods:80 cases of benign prostatic hyperplasia were randomly divided into two groups,treatment group,40 cases of oral Longchangkeli;40 cases of the control group,oral Longbishu,one month a course of treatment for the two groups are the treatment of 3 courses.Of clinical symptoms before and after treatment,IPSS,maximum urinary flow rate,residual urine volume,prostate volume,such as comparative analysis of indicators.Some experiments using rats injected testosterone propionate after castration-induced prostatic hyperplasia law model,after oral administration of 30d executed.Removal of prostate tissue wet weight was measured using two-step method of PV particles and infirmity infirmity closed Chang Shu intervention organizations prostatic hyperplasia in rats bcl-2 gene testing.Resulsts:Clinical observation:In the treatment group,the total effective rate 78.4%.In the control group,the total effective rate was 64.7%.With X~2 test, the difference between the two groups significant(P＜0.05),which show that the effect of Longchangkeli is better than the control group in treatment.The experimental results show that wet weight of prostate:blank group 0.61±0.03; model group 0.95±0.04;Longbishu group 0.73±0.02;the low dose of Longchangkeli 0.80±0.05;the normal dose of Longchangkeli 0.78±0.07;the high dose of Longchangkeli 0.68±0.03;compared with model group P＜0.05. Prostate index:blank group 0.143±0.006;model group 0.226±0.008; Longbishu group 0.172±0.004;the low dose of Longchangkeli 0.199±0.012; the normal dose of Longchangkeli 0.181±0.010;the high dose of Longchangkeli 0.168±0.003;compared with model group P＜0.05.Expression effect study of Longchangkeli on prostate’s bcl-2 in benign prostate hyperplasia rats(average optical density):blank group 0.089±0.010;model group 0.131±0.005;Longbishu group 0.093±0.015;the low dose of Longchangkeli 0.109±0.001;the normal dose of Longchangkeli 0.097±0.003; the high dose of Longchangkeli 0.091±0.003;compared with model group P＜0.05.Conclusion:1.The Longchangkeli can obviously alleviate the symptoms and signs of the BPH.The results show that the effect of Longchangkeli on the BPH was superior to that of Longbishu.2.Longchangkeli can effectively reduce the model of rat prostate wet weight,reduce the pathological changes.Its mechanism of rat prostate may be reduced bcl-2 gene expression in the promotion of prostate cell apoptosis.更多还原